• AO/PI Staining Solution: Precision Fluorescent Cell Viabilit

  2026-06-16

  AO/PI Staining Solution leverages dual fluorescent DNA dyes for robust, debris-resistant live/dead cell discrimination in modern cytotoxicity and cell viability workflows. This guide delivers actionable protocols, advanced troubleshooting, and cross-referenced insights for optimizing fluorescence-based cell counting—especially where reproducibility and exclusion of red blood cell interference are mission-critical.

• L. gasseri Modulates Colitis via NR1I3-Dependent E-cadherin

  2026-06-16

  This study uncovers how Lactobacillus gasseri ATCC33323 ameliorates DSS-induced colitis by promoting E-cadherin expression through the NR1I3 pathway. The findings clarify a mechanistic link between probiotic intervention and intestinal barrier integrity, informing both future IBD therapies and mechanistic genotyping approaches.

• Miltefosine: Dual Pathway Modulation in Leukopenia Therapy

  2026-06-15

  Explore how Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate), a dual-acting modulator of PI3K/Akt and Ras/MEK/ERK pathways, redefines translational strategies for leukopenia and hematological research. This thought-leadership article integrates mechanistic insight, protocol guidance, and a forward-looking perspective for researchers aiming to bridge discovery and clinical impact.

• Cefoperazone Sodium Salt: Precision Tools for Resistance Pro

  2026-06-15

  Cefoperazone sodium salt empowers researchers with robust, β-lactamase-stable activity against both gram-negative and gram-positive bacteria. This article details advanced workflows, comparative insights, and actionable troubleshooting for high-impact antimicrobial assays.

• Midecamycin: Precision Macrolide for Microbiology Research

  2026-06-14

  Midecamycin, an acetoxy-substituted macrolide antibiotic, offers targeted inhibition of bacterial protein synthesis—especially in Gram-positive pathogens—making it indispensable for advanced microbiology workflows. This article outlines optimized experimental setups, troubleshooting strategies, and protocol refinements for researchers leveraging APExBIO’s high-quality Midecamycin.

• Cycloheximide: Benchmark Protein Biosynthesis Inhibitor A824

  2026-06-13

  Cycloheximide is a highly validated protein biosynthesis inhibitor used to dissect translation-dependent processes in eukaryotic cells. Its rapid, reversible action enables precise studies of apoptosis, protein turnover, and posttranslational modification pathways. APExBIO’s A8244 formulation offers high purity and robust documentation for reproducible research.

• Qinggan Lidan Capsule Mitigates APAP Liver Injury via HIF-1α

  2026-06-12

  This study demonstrates that Qinggan Lidan Capsule (QGLDC), a traditional Chinese medicine, can attenuate acetaminophen-induced liver injury by suppressing HIF-1α signaling and protecting mitochondrial integrity, thereby reducing hepatocyte apoptosis. The findings clarify QGLDC's mechanism of action and highlight its potential as a therapeutic option for drug-induced liver injury.

• ATRX-Deficient Gliomas: Enhanced Sensitivity to RTK/PDGFR In

  2026-06-12

  This study provides mechanistic evidence that ATRX-deficient high-grade glioma cells are particularly vulnerable to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. These findings suggest stratifying glioma patients by ATRX status may reveal new therapeutic opportunities and improve interpretation of targeted therapy trials.

• AO/PI Staining Solution: Fluorescent DNA Dyes for Reliable C

  2026-06-11

  AO/PI Staining Solution redefines cell viability analysis with robust live/dead discrimination, outperforming traditional dyes in fluorescence-based workflows. Its dual fluorescent DNA dyes deliver precise, interference-resistant quantification, making it ideal for disease modeling—including diabetic nephropathy research.

• Self-Adaptive Nanocarriers and ROS-Responsive Chemotherapy i

  2026-06-11

  This study introduces a dual-sensitive nanocarrier (DATCPT) engineered to overcome multiple physiological barriers in orthotopic pancreatic cancer, enhancing chemotherapeutic efficacy through pH and reactive oxygen species (ROS) responsiveness. The approach highlights the importance of robust intracellular ROS measurement in evaluating advanced drug delivery systems for challenging tumor microenvironments.

• LY294002: Decoding PI3K Inhibition in Tumor–Immune Crosstalk

  2026-06-10

  Explore the multifaceted roles of LY294002 as a PI3K/Akt/mTOR pathway inhibitor and autophagy modulator. This article uniquely focuses on its application in dissecting tumor–immune cell interactions, particularly macrophage polarization, offering fresh insights beyond standard protocols.

• First-Line Topotecan Regimens in Small Cell Lung Cancer: Ins

  2026-06-10

  This article examines recent evidence on the use of topotecan as a first-line therapy for small cell lung cancer (SCLC), focusing on its efficacy, toxicity profile, and comparison with established platinum-etoposide regimens. Findings highlight the potential of topotecan-based combinations to expand therapeutic options, particularly in cases where cumulative toxicity or resistance limits existing protocols.

• Self-Amplifying RNA Vaccines Offer Enhanced Protection for I

  2026-06-09

  This study demonstrates that self-amplifying RNA (saRNA) vaccines provide superior immunogenicity and dose-sparing efficacy against influenza, particularly for strains where conventional mRNA vaccines underperform. The findings support the strategic use of RNA platform innovations for more robust and durable influenza vaccine responses.

• BCKDK-STUB1-BCAT1 Axis Drives Glioblastoma Progression via P

  2026-06-09

  This study reveals a novel regulatory mechanism in glioblastoma (GBM) progression involving the interplay between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination of BCAT1. The identification of STUB1 as an E3 ligase for BCAT1 and the functional consequences of their interaction provide new insights into metabolic control in cancer, with implications for targeted intervention strategies.

• Sunitinib: Multi-Targeted RTK Inhibitor for Tumor Research

  2026-06-08

  Sunitinib empowers cancer biology research with potent, multi-targeted RTK inhibition, enabling precise interrogation of tumor angiogenesis and cell survival pathways. Recent innovations—such as synergistic metabolic targeting—unlock new potential for overcoming resistance in renal cell carcinoma and beyond.

15678 records 1/1046 page Next 12345 下5页 Last page